Press Releases 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 Eagle Announces Update on Delisting from Nasdaq and SEC Deregistration 11/15/24 Eagle Pharmaceuticals Appoints Christopher Krawtschuk as Chief Financial Officer 11/12/24 Eagle Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan 10/31/24 Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq 8/27/24 Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq 5/22/24 Eagle Pharmaceuticals Announces a Trial in Progress Presentation of Phase 2/3 Study of Intravenous Amisulpride as Prevention of Postoperative Nausea and Vomiting in Pediatric Patients at the Upcoming Society for Ambulatory Anesthesia (SAMBA) 2024 Annual Meeting 4/30/24 Eagle Pharmaceuticals to Present Additional Data from Phase III Trial Demonstrating Sustained Response of Amisulpride for the Rescue Treatment of Postoperative Nausea and Vomiting (PONV) at the Upcoming ASPAN 2024 National Conference in Orlando, Florida 4/15/24 Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Annual Report on Form 10-K 4/12/24 Eagle Pharmaceuticals Provides Update on Bendamustine Intellectual Property Portfolio 1/18/24
